CA2945531C - Signature d'expression d'arnmi dans la classification des tumeurs thyroidiennes - Google Patents

Signature d'expression d'arnmi dans la classification des tumeurs thyroidiennes Download PDF

Info

Publication number
CA2945531C
CA2945531C CA2945531A CA2945531A CA2945531C CA 2945531 C CA2945531 C CA 2945531C CA 2945531 A CA2945531 A CA 2945531A CA 2945531 A CA2945531 A CA 2945531A CA 2945531 C CA2945531 C CA 2945531C
Authority
CA
Canada
Prior art keywords
mir
hsa
classifier
thyroid
microrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2945531A
Other languages
English (en)
Other versions
CA2945531A1 (fr
Inventor
Zohar BARNETT-ITZHAKI
Gila Lithwick Yanai
Eti Meiri
Yael Spector
Hila Benjamin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Publication of CA2945531A1 publication Critical patent/CA2945531A1/fr
Application granted granted Critical
Publication of CA2945531C publication Critical patent/CA2945531C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de classification des tumeurs thyroïdiennes basée sur l'analyse des profils d'expression de micro-ARN spécifiques dans des échantillons obtenus par aspiration à l'aiguille fine. La classification des tumeurs thyroïdiennes selon une signature d'expression de micro-ARN permet d'optimiser le diagnostic et le traitement, et de déterminer également une thérapie spécifique de la signature.
CA2945531A 2014-05-13 2015-05-13 Signature d'expression d'arnmi dans la classification des tumeurs thyroidiennes Expired - Fee Related CA2945531C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461992756P 2014-05-13 2014-05-13
US201461992531P 2014-05-13 2014-05-13
US61/992,531 2014-05-13
US61/992,756 2014-05-13
US201462069353P 2014-10-28 2014-10-28
US62/069,353 2014-10-28
US201562139066P 2015-03-27 2015-03-27
US62/139,066 2015-03-27
PCT/US2015/030564 WO2015175660A1 (fr) 2014-05-13 2015-05-13 Signature d'expression d'arnmi dans la classification des tumeurs thyroïdiennes

Publications (2)

Publication Number Publication Date
CA2945531A1 CA2945531A1 (fr) 2015-11-19
CA2945531C true CA2945531C (fr) 2018-01-30

Family

ID=54480610

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2945531A Expired - Fee Related CA2945531C (fr) 2014-05-13 2015-05-13 Signature d'expression d'arnmi dans la classification des tumeurs thyroidiennes

Country Status (7)

Country Link
EP (1) EP3143162A4 (fr)
JP (1) JP6216470B2 (fr)
CN (1) CN106460053A (fr)
BR (1) BR112016026575A2 (fr)
CA (1) CA2945531C (fr)
IL (1) IL248639A0 (fr)
WO (1) WO2015175660A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106434872A (zh) * 2016-08-11 2017-02-22 河南大学 一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑152‑3p及其应用
CN107385093A (zh) * 2017-09-07 2017-11-24 青岛大学 引物组合物及其应用和应用其的产品及产品的使用方法
CN107723365B (zh) * 2017-09-11 2019-10-01 朱伟 一种与肺鳞癌辅助诊断相关的血浆miRNA标志物及其应用
CN108038352B (zh) * 2017-12-15 2021-09-14 西安电子科技大学 结合差异化分析和关联规则挖掘全基因组关键基因的方法
CA3088939A1 (fr) * 2018-01-05 2019-07-11 Visiongate, Inc. Genotypage morphometrique de cellules par tomographie optique pour detecter une charge de mutation de tumeur
BR102018003587A2 (pt) * 2018-02-23 2020-07-07 Onkos Diagnósticos Moleculares Ltda Me método e kit para detecção de tipo de tumor de tireoide
CN108721318B (zh) * 2018-05-16 2021-06-25 广东药科大学 miR-125b和化疗剂在制备治疗甲状腺癌的药物中的应用
JP7378739B2 (ja) * 2018-08-10 2023-11-14 東レ株式会社 前立腺がんの検出のためのキット、デバイス及び方法
CN109700824A (zh) * 2019-01-08 2019-05-03 上海长海医院 miR-31及其类似物在制备预防或治疗血管内皮损伤的药物中的应用
CN110499367B (zh) * 2019-08-09 2022-11-22 深圳市第二人民医院 生物标志物及其应用
CN113025714B (zh) * 2021-03-23 2022-05-24 华中科技大学同济医学院附属同济医院 用于甲状腺乳头状癌颈侧方淋巴结转移诊断的miRNA生物标志物及检测试剂盒
CN116769922B (zh) * 2023-08-24 2023-11-24 四川大学华西医院 检测循环sEV RNA试剂的用途、试剂盒和诊断系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154008A1 (fr) * 2010-06-11 2011-12-15 Rigshospitalet Classification de micro-arn de néoplasie folliculaire de la thyroïde
JP2014511677A (ja) * 2011-03-22 2014-05-19 コーネル・ユニバーシティー 鑑別困難な良性甲状腺病変と悪性甲状腺病変との識別法
US20130142728A1 (en) * 2011-10-27 2013-06-06 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Also Published As

Publication number Publication date
EP3143162A1 (fr) 2017-03-22
IL248639A0 (en) 2017-01-31
WO2015175660A1 (fr) 2015-11-19
BR112016026575A2 (pt) 2017-12-12
CN106460053A (zh) 2017-02-22
JP2017521051A (ja) 2017-08-03
EP3143162A4 (fr) 2017-04-26
JP6216470B2 (ja) 2017-10-18
CA2945531A1 (fr) 2015-11-19

Similar Documents

Publication Publication Date Title
US9708667B2 (en) MiRNA expression signature in the classification of thyroid tumors
CA2945531C (fr) Signature d'expression d'arnmi dans la classification des tumeurs thyroidiennes
KR101900872B1 (ko) 조기 대장암 검출을 위한 혈장 마이크로rna
Wu et al. Next‐generation sequencing of microRNAs for breast cancer detection
US20180105888A1 (en) Methods and Kits for Detecting Subjects at Risk of Having Cancer
Li et al. Identification of aberrantly expressed miRNAs in rectal cancer
US10457994B2 (en) 4-miRNA signature for predicting clear cell renal cell carcinoma metastasis and prognosis
US20110160290A1 (en) Use of extracellular rna to measure disease
AU2018202963B2 (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
MX2013013746A (es) Biomarcadores para cancer de pulmon.
WO2009133915A1 (fr) Marqueur de cancer, procédé d’évaluation du cancer utilisant le marqueur de cancer et réactif d’évaluation
CA2836836A1 (fr) Procedes et dispositifs pour le pronostic d'une rechute du cancer
US9068232B2 (en) Gene expression signature for classification of kidney tumors
WO2011154008A1 (fr) Classification de micro-arn de néoplasie folliculaire de la thyroïde
WO2017079571A1 (fr) Procédé pour l'identification de patients à risque de carcinome à cellules squameuses orales
JP2022536502A (ja) 癌を治療するための組成物および方法
US20140243230A1 (en) Gene expression signature for classification of kidney tumors
Attia et al. Altered expression of microRNAs in the bone marrow of multiple myeloma patients and their relationship to cytogenetic aberrations
KR20130098669A (ko) 위암의 림프절 전이 진단 마커로서의 혈청 ｍｉＲＮＡ
Rghebi Circulating nucleic acids as biomarkers of breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161220

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831